Necuparanib also has an FDA Orphan Drug indication for the same indication (#msg-102765888). The phase-1 data from the ongoing phase-1/2 trial testing Gemzar+Abraxane ± Necuparanib were reported in detail at MNTA’s R&D Day in October (#msg-107057169).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.